Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of sacituzumab govitecan for long-term safety in metastatic solid tumors
2023-505336-34-00Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of sacituzumab govitecan in Metastatic solid neoplasm, sponsored by Gilead Sciences. Primary endpoints: Percentage of participants experiencing any AE, Percentage of participants experiencing any SAE and 1 more. Started Oct 2023; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
Metastatic solid neoplasm
Beyond the preview
Go deeper on 2023-505336-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505336-34-00.